18:31 , Aug 17, 2018 |  BC Week In Review  |  Financial News

RegenxBio raises $201.8M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $201.8 million through the sale of 3.1 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. The number includes a 405,000 share...
20:46 , Aug 13, 2018 |  BC Extra  |  Preclinical News

Polygenic scores increase disease risk prediction

Two studies in Nature Genetics suggest that aggregating SNPs, instead of assessing single SNPs, to generate risk scores from genome-wide association studies (GWAS) could improve predictions for disease risk. The use of individual gene variants identified...
18:37 , Aug 10, 2018 |  BC Extra  |  Financial News

RegenxBio raises $175.5M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James. On Wednesday, the company disclosed a treatment-related...
00:21 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

RegenxBio discloses second serious AE for hypercholesterolemia gene therapy

RegenxBio Inc. (NASDAQ:RGNX) said RGX-501 led to a second treatment-related serious adverse event in a Phase I/II trial to treat homozygous familial hypercholesterolemia (HoFH). The open-label, international trial has enrolled six patients to receive a single...
00:01 , Aug 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The authors...
20:26 , Jul 20, 2018 |  BioCentury  |  Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
16:53 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

Intellia’s delivery address

Intellia Therapeutics Inc. (NASDAQ:NTLA) published data supporting its lead in vivo gene editing program and providing proof of concept for its delivery technology this week. Now, the company wants to see just how far the...
01:15 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Mouse studies suggest inhibiting ARHGEF1 could help treat atherosclerosis. In an LDLR-deficient mouse model of atherosclerosis, ARHGEF1 knockout decreased the formation of atherosclerotic lesions compared with normal expression. In two bone marrow-ablated, LDLR-deficient mouse...
19:20 , Sep 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular In vitro studies identified a peptide inhibitor of PCSK9 that could help reduce the risk of major cardiovascular events in patients with dyslipidemia and related conditions. Screening of a peptide library in PCSK9-binding assays...